ARMMs give a leg-up to novel biotherapeutics

By engineering naturally existing arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicles (known as ARMMs), Vesigen Therapeutics’ platform enables the effective delivery of novel biotherapeutics to specific tissues and cell types.

Nonviral Platforms Streamline Gene Therapy Delivery

Complications of viral vectors can be avoided with DNA plasmids, engineered vesicles, cell-penetrating proteins, and other nonviral alternatives.

LinkeIn Twitter